Please login to the form below

Not currently logged in
Email:
Password:

Invokana

This page shows the latest Invokana news and features for those working in and with pharma, biotech and healthcare.

FDA adcomm split on Sanofi’s type 1 diabetes drug

FDA adcomm split on Sanofi’s type 1 diabetes drug

Current SGLT2-selective drugs – such as Johnson &Johnson’s Invokana, Eli Lilly/Boehringer Ingelheim's Jardiance and Farxiga from AstraZeneca – are approved only for type 2 diabetes.

Latest news

More from news
Approximately 19 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken Invokana (the 2nd entrant).

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including Janssen/Mitsubishi Tanabe's Invokana (canagliflozin), Sanofi/Chugai's tofogliflozin and

  • Pharma deals during April 2013 Pharma deals during April 2013

    Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its SGLT2 inhibitor—Invokana (canagliflozin). In this deal, Merck gets to extend the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics